Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [(18)F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors of therapeutic efficacy. Contrast enhanced MRI and [(18)F]-fluorodeoxyglucose (FDG)–PET are routinely used in clinical settings; their ability to forecast the therapeutic response is controve...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Corroyer-Dulmont, Aurélien, Pérès, Elodie A., Petit, Edwige, Guillamo, Jean-Sébastien, Varoqueaux, Nathalie, Roussel, Simon, Toutain, Jérôme, Divoux, Didier, MacKenzie, Eric T., Delamare, Jérôme, Ibazizène, Méziane, Lecocq, Myriam, Jacobs, Andréas H., Barré, Louisa, Bernaudin, Myriam, Valable, Samuel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2013
Aiheet:
Basic and Translational Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3534417/
https://ncbi.nlm.nih.gov/pubmed/23115160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nos260
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia